Zuclopenthixol

Bezeichnung:Zuclopenthixol

CAS-Nr53772-83-1

Englisch Name:Zuclopenthixol

CBNumberCB1875393

SummenformelC22H25ClN2OS

Molgewicht400.96

MOL-Datei53772-83-1.mol

Synonyma

Zuclopenthixol

Zuclopenthixol physikalisch-chemischer Eigenschaften

Schmelzpunkt	56-60°C
Siedepunkt	577.4±50.0 °C(Predicted)
Dichte	1.289±0.06 g/cm3(Predicted)
storage temp.	-20°C Freezer, Under Inert Atmosphere
Löslichkeit	Chloroform (Slightly), Methanol (Slightly)
Aggregatzustand	Solid
pka	14.96±0.10(Predicted)
Farbe	White to Off-White
CAS Datenbank	53772-83-1

Gefahreninformationscode (GHS)

Zuclopenthixol Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Zuclopenthixol is a dopamine receptor antagonist (K_is = 9.8 and 1.5 nM for D₁ and D₂ receptors, respectively). It also binds to serotonin (5-HT) receptor subtypes 5-HT₂ and 5-HT₆, α₁-adrenergic, and histamine receptors (K_is = 7.6, 3, 33, and 169 nM, respectively) but not α₂-adrenergic receptors (K_i = >4,300 nM). Zuclopenthixol inhibits dopamine-induced accumulation of cAMP in rat striatal homogenates (IC₅₀ = 330 nM; K_i = 16 nM). It decreases stereotypic behavior induced by methylphenidate in mice (ED₅₀ = 0.8 μmol/kg) and by apomorphine in rats and dogs (ED₅₀s = 6.0 and 1.3 μmol/kg, respectively). Zuclopenthixol (0.7 and 1.4 mg/kg, i.p.) administered prior to testing enhances memory retrieval in rats in an inhibitory avoidance task without affecting locomotor activity.
Beschreibung
Zuclopenthixol is a kind of antipsychotic agent. It is a thioxanthene-based neuroleptic with in vivo action similar to the phenothiazine antipsychotics through antagonizing D1 and D2 dopamine receptors. It has three major formulations form including zuclopenthixol decanoate, zuclopenthixol acetate, and zuclopenthixol dihydrochloride. It can be used for the treatment of schizophrenia and bipolar mania. Besides antagonizing the D1 and D2 dopamine receptors, Zuclopenthixol can also take effect through antagonizing alpha1-adrenergic and 5-HT2 receptors. It can also weakly block the histamine H1 receptor.
Chemische Eigenschaften
Pale Yellow Low Melting Solid
Verwenden
Zuclopenthixol is an anti-psychotic drug. It is an inhibitor of coxsackievirus B3. Also, it is an intermediate used in the synthesis of Zuclopenthixol Decanoate (Z701490), which is used in the maintenance treatment of chronic schizophrenic patients. It is one of the three distinct formulations of Zuclopenthixol namely, zuclopenthixol dihydrochloride, zuclopenthixol acetate or Acuphase and zuclopenthixol decanoate.
Verwenden
The labelled cis(Z)-form of Clopenthixol. Thioxanthene neuroleptic. Antipsychotic.
Verwenden
The cis(Z)-form of Clopenthixol. Thioxanthene neuroleptic. Antipsychotic.
Definition
ChEBI: The (Z)-isomer of clopenthixol.
Clinical Use
Antipsychotic for schizophrenia and other psychoses
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effects.
Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval - avoid with amiodarone and disopyramide.
Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and parenteral erythromycin - avoid
Antidepressants: increased level of tricyclics; possible increased risk of convulsions with vortioxetine.
Antiepileptics: anticonvulsant effect antagonised.
Antimalarials: avoid concomitant use with artemether/lumefantrine.
Antipsychotics: avoid concomitant use of clozapine with depot preparations in case of neutropenia; possible increased risk of ventricular arrhythmias with risperidone.
Antivirals: concentration possibly increased with ritonavir.
Atomoxetine: increased risk of ventricular arrhythmias.
Anxiolytics and hypnotics: increased sedative effects.
Beta-blockers: increased risk of ventricular arrhythmias with sotalol - avoid.
Cytotoxics: increased risk of ventricular arrhythmias with vandetanib - avoid; increased risk of ventricular arrhythmias with arsenic trioxide.
Stoffwechsel
Metabolism of zuclopenthixol is by sulphoxidation, sidechain N-dealkylation and glucuronic acid conjugation.
The sulphoxide metabolites are mainly excreted in the urine while unchanged drug and the dealkylated form tend to be excreted in the faeces.
Einzelnachweise
https://www.drugbank.ca/drugs/DB01624
https://en.wikipedia.org/wiki/Tiabendazole

Zuclopenthixol Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

53772-83-1, Zuclopenthixol Verwandte Suche:

Send Inquriy